TauRx was founded in 2002 in Singapore and has research facilities in Aberdeen. Our mission is to discover, develop and commercialise products for the diagnosis and treatment of neurodegenerative diseases caused through protein aggregation. The early research of Professor Wischik led to the first identification of tau protein discovered by Alzheimer.
Tau pathology is widely recognised as a principal driver of clinical dementia in AD and Tau Aggregation Inhibitors (TAIs) target the formation or aggregation of tau protein ‘tangles’ in the brain. Three completed phase 3 studies of our second-generation TAI have informed the design of our fully randomised LUCIDITY study, with results expected mid-2022. www.taurx.com
It is estimated that there are close to 50 million people currently living with AD and that this figure will continue to increase to 75 million by 2030 and to 132 million by 2050. These figures, based as they are on the clinically visible stages of disease, underestimate the global number with early stages of progressive tau pathology, which TauRx estimates to be closer to 500 million already now, with 60% of these in Asia.
GT Diagnostics UK Ltd (a joint venture between Genting Bhd and TauRx), aims to transform the diagnostic pathway by launching inexpensive and accurate assessment tools for dementia. Readily deployable e-platform tools for use as home-based well-being apps, with professional tools for experts targeting diagnosis and disease monitoring are due for launch this year. Additionally, tools have capability to support financial and professional services, residential and non-residential care provision, and specialised dementia centres. https://www.gtdiag.com/